The construction of an impressive high-tech purpose-built R&D and manufacturing facility that will be a vital hub for one of the world’s leading suppliers of reagents enabling research into diagnostics and vaccines for emerging and endemic infectious diseases has been completed at Oxford Technology Park.
The new 49,000 sq ft two-storey building with a sleek design frontage, 48 car parking spaces (ten with EV charging points) and a mixture of bespoke laboratory, Grade A office, and logistic operations, has been let to LGC’s The Native Antigen Company (TNAC), on a ten-year lease.
TNAC is one of the world’s leading suppliers of high-quality reagents for infectious diseases. Their comprehensive portfolio of antigens and antibodies provides their customers with the critical components needed to build in vitro diagnostic tests, support vaccine development, and further academic research.
TNAC was awarded ‘Best COVID-19 Responder at the 2020 OBN Awards’ for their efforts in supporting the research and development of diagnostics and vaccines for COVID-19. The exciting new hub will be ISO 9001 certified and will operate alongside LGC Clinical Diagnostics’ ISO 13485 accredited facilities in the US.
The building has been constructed alongside the landmark three-storey 30,000 sq ft lab-enabled office building fronting Langford Lane and the Oxford London airport, offering suites from 4,000 sq ft and ready for occupation at the beginning of this year.
It is also well-positioned to make use of the planned facilities at Oxford Technology Park, located adjacent to the Innovation Quarter – due for completion this spring and just a stone’s throw away from the park’s Premier Inn hotel and Beefeater restaurant.
Nick Roesen, COO of The Native Antigen Company, said: “The new facility provides us with the perfect opportunity to expand our operations, following the acquisition of The Native Antigen Company in July 2020 by LGC.
The building has been designed to meet our exact specifications, which will enable us to work more efficiently and effectively. We are also excited about being part of a new science and technology community at Oxford Technology Park.”
Angus Bates, Owner and Developer of Oxford Technology Park, said: “We are thrilled to be working with The Native Antigen Company and looking forward to growing the science and technology community around them.”
Oxford Technology Park is a major new science and technology park providing the next generation of office, Research & Development, laboratory and production space at the heart of Oxfordshire’s Knowledge Economy spine.
Extending over 20 acres and with planning consent for more than 400,000 sq ft of built space, Oxford Technology Park is destined to form an integral part of the city’s science and technology-based expansion to the North.
Oxford Technology Park is a major new science and technology park providing the next generation of Office and R&D space at the heart of Oxfordshire’s A34 knowledge economy spine.
Construction of over 150,000 sq ft is currently underway, consisting of three distinct buildings, starting with a landmark, three-storey lab-enabled Building One due for completion in April 2022.
Situated on the entrance into Oxford Technology Park, fronting Langford Lane and the Oxford London airport, this prestigious building offers 34,125 sq. ft. of flexible space, available to let in suites from 4,140 sq. ft. for office, laboratory, and R&D use.
Adjacent to Building One will be the HQ facility for The Native Antigen Company, quickly followed by the next phase of development with the Innovation Quarter, which will be ready for fit-out in the summer.
Nick Roesen (COO of The Native Antigen Company), Lauren Bates (Development Director at Oxford Technology Park) and Euan O’Sullivan (President and Chief Executive Officer of LGC Group).